A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 14
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.
详细描述
Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors, the vast majority of patients will develop secondary resistance to these agents.
The therapeutic options of patients with advanced GIST with resistance (or intolerance) to imatinib and sunitinib remain then very limited and prognosis of patients are very poor.
Nilotinib has an inferior activity in first line setting as compared to imatinib. Sorafenib has been evaluated in off-label and compassionate use studies with a median PFS close to 3 to 4 months, and a median overall survival close to 9 months with few prolonged tumor control and limited availability.
Regorafenib was tested in a phase II and a randomized phase III trial (GRID) in this setting , and provided a significant PFS advantage with no significant improvement in OS.
There are no recognized standard options in patients whose tumors progress after 3 or more TKIs. The recently updated guidelines from ESMO in 2014, included the reintroduction of imatinib in an attempt to control the progression of the sensitive cell clones, and on the basis of the results of the RIGHT study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years at the day of consenting to the study.
- •Patient must have histologically confirmed diagnosis of GIST.
- •Disease must be locally advanced or metastatic.
- •Patient who failed (disease progression and/or intolerance) previously at least to imatinib and sunitinib.
- •Nota Bene: patients with more than 2 previous anticancer treatments are eligible.
- •Patient must have evidence of measurable disease as per the RECIST version 1.1 (Appendix 2).
- •Patient must have documented disease progression. I
- •ECOG performance status 0, 1 or 2 (Appendix 3).
- •Patient must have normal organ and bone marrow function as defined below:
- •Hematologic
- •Absolute neutrophil count (ANC) ≥ 1.5 Gi/L
- •Haemoglobin ≥ 9 g/dl (5.6 mmol/l) (subjects may not have had a transfusion within 7 days of screening assessment)
- •Platelets ≥ 100 Gi/l
- •Coagulation panel
- •Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 X upper limit of normal (ULN)
- •Partial thromboplastin time (PTT) ≤ 1.2 X ULN Subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation.
- •Total bilirubin ≤ 1.5 X ULN
- •AST and ALT ≤ 2.5 X ULN
- •Serum creatinine ≤ 1.5 mg/dl (133 µmol/l) Or, if greater than 1.5 mg/dl: calculated creatinine clearance ≥ 50 ml/min
- •Urine Protein to Creatinine ratio (UPC) < 1; If UPC > 1, then a 24-hour urine protein must be assessed. Subjects must have a 24-hour urine protein value <1g.
- •Patient and his/her partner using an effective contraception as defined in Appendix
- •Patient able to understand and willingness for follow-up visits. I
- •Patient covered by a medical insurance. I
- •Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to any study-specific procedure.
排除标准
- •Patient with a documented mutation in PDGFRA exon 18 (D842V substitution).
- •Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:
- •Active peptic ulcer disease
- •Known intraluminal metastatic lesions with risk of bleeding
- •Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
- •Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
- •Malabsorption syndrome
- •Major resection of the stomach or small bowel.
- •Any active/uncontrolled infection, including known infection with HIV, Hepatitis B or Hepatitis C.
- •Corrected QT interval (QTc) > 480 msecs using Bazett's formula
- •History of any one or more of the following cardiovascular conditions within the past 6 months prior to the first dose of study drug:
- •Cardiac angioplasty or stenting
- •Myocardial infarction
- •Unstable angina
- •Coronary artery bypass graft surgery
- •Symptomatic peripheral vascular disease
- •Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) classification.
- •Poorly controlled arterial hypertension (Systolic blood pressure: 150mmHg / Diastolic blood pressure: 90mmHg).
- •Note: Patients with high blood pressure can be enrolled provided that the hypertension is well controlled at a stable dose of antihypertensive therapy for at least 1 week prior to lenvatinib start).
- •Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).
- •Evidence of active bleeding or bleeding diathesis. E
- •Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.
- •Clinically significant haemoptysis within 8 weeks of first dose of study drug.
- •Any serious and/or unstable pre-existing medical, psychiatric, or other condition (geographic, social...) that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
- •Unable or unwilling to discontinue use of prohibited medications list in Section 6.3 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.
- •Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.
- •Inability to swallow E
- •Any contraindication to Lenvima®, according to its Summary of Product Characteristics E
- •History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition of lenvatinib E
- •Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.
- •Pregnant or breastfeeding women. Women of childbearing potential (Appendix 1) are required to have a negative serum pregnancy test within 72 hours prior to study treatment start. A positive urine test must be confirmed by a serum pregnancy test Note: Female if applicable, subjects should discontinue breast-feeding prior to the first dose of study drug and should refrain from breastfeeding throughout the treatment period and for 14 days following the last dose of study drug.
- •Patient under tutorship or curatorship.
研究组 & 干预措施
Lenvatinib + Best Supportive Care
干预措施: Lenvatinib (Drug)
Lenvatinib + Best Supportive Care
干预措施: Best supportive care (Other)
Placebo + Best Supportive Care
干预措施: Placebo (Drug)
Placebo + Best Supportive Care
干预措施: Best supportive care (Other)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: Up to 30 months
PFS, defined as the time from the date of randomisation to the date of the first documented radiological progression (RECIST 1.1) or death due to any cause. PFS will be estimated using the Kaplan-Meier method and will be described in terms of median PFS per arm, and hazard ratio for progression between the 2 arms. Associated 2-sided 95% CI for the estimates will be provided.
次要结局
- Objective Response Rate (ORR) for patient in the blinded part of the study(Up to 30 months)
- Best Overall Response (BOR) for patient in the blinded part of the study(Up to 30 months)
- Overall Survival (OS)(Up to 30 months)
- Quality of Life (QoL) for patient in the blinded part of the study(Up to 30 months)
- Patient's tolerance to treatment(Up to 30 months)
- Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group(Up to 30 months)